October 22, 2018 Clinical Research/Diagn. M&A, Partnerships

Quanterix Announces Collaboration With Oncogenesis to Develop Cervical Screening Test

OCTOBER 22, 2018 Quanterix’ technology to be used in multiplex diagnostic test for cervical disease detection Lexington, Mass. – October 22, 2018 — Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced a collaboration agreement with OncoGenesis, a molecular protein-based cervical screening company, to develop a quantitative, protein... Read more

October 22, 2018 Clinical Research/Diagn. M&A, Partnerships

Announcement of Participation in AMED Project “Research and development of core technologies for gene and cell therapy”

2018/10/22 Kusatsu/Shiga, Japan — October 22, 2018 – Takara Bio Inc. announces that it is participating in “Research and development of core technologies for gene and cell therapy” (Project) undertaken by Japan Agency for Medical Research and Development (AMED: https://www.amed.go.jp/en/index.html) since FY2018, under which Takara Bio will work on the development for large-scale production technologies of... Read more

October 18, 2018 Clinical Research/Diagn. M&A, Partnerships

Exact Sciences Strengthens Pipeline Capabilities With Acquisition Of Biomatrica, A Leading Provider Of Biological Sample Preservation Technology

10/18/2018 Technology Promotes High-Quality Results from Liquid Biopsy Cancer Tests MADISON, Wis. and SAN DIEGO, Oct. 18, 2018 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS) today announced the acquisition of Biomatrica, a leading developer, manufacturer and provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry. Biomatrica’s sample collection... Read more

October 17, 2018 Clinical Research/Diagn. Lab Top-10 Product Launch

Thermo Fisher Scientific CE Marks Oncomine Dx Target Test

CARLSBAD, Calif., Oct. 17, 2018 /PRNewswire/ — Marking a milestone in bringing its Oncomine Dx Target Test to Europe, Thermo Fisher Scientific today announced that it has CE-IVD marked its next-generation sequencing (NGS)-based solution that screens biomarkers across solid tumors. Thermo Fisher will highlight the test during the European Society for Medical Oncology (ESMO) Congress... Read more

October 16, 2018 Clinical Research/Diagn. Licensing, IP, and Legal Life Science Tools Product Launch

BD Launches Molecular Test For Detecting Tuberculosis And Multi-Drug Resistant TB

BD MAX™ MDR-TB Panel Obtains CE-IVD Status in Europe FRANKLIN LAKES, N.J., Oct. 16, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the availability of the BD MAX™ MDR-TB panel in Europe. Clinicians can use the test to simultaneously detect bacteria that cause tuberculosis (TB) and determine if the bacteria... Read more

October 16, 2018 Clinical Research/Diagn.

Reminder: Invitation to Roche's live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress

Basel, 16 October 2018 Reminder: Invitation to Roche’s live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Monday, 22 October 2018, to discuss key data presented on the Roche Group’s oncology portfolio and pipeline during the... Read more

October 16, 2018 Clinical Research/Diagn. Lab Top-10 Life Science Tools M&A, Partnerships

Thermo Fisher Scientific Custom Microarrays Drive Large-Scale Genotyping Study of Finnish Population

Thermo Fisher Scientific Custom Microarrays Drive Large-Scale Genotyping Study of Finnish Population FinnGen, a first-of-its-kind study of 500,000 individuals, combines genomics and health record data to better understand disease origins and improve human health SANTA CLARA, Calif., Oct. 16, 2018 /PRNewswire/ — Thermo Fisher Scientific today announced facilitation of the next phase of the FinnGen precision... Read more

October 16, 2018 Clinical Research/Diagn. Lab Top-10 Liq. Handling & Robotics M&A, Partnerships

Bruker Completes Acquisition of Majority Interest in Infectious Disease Molecular Diagnostics Company Hain Lifescience GmbH

– Acquisition expands Bruker’s Microbiology & Diagnostics business with profitable Molecular Diagnostics portfolio and substantial innovation pipeline – Novel Fluorocycler™ XT thermal cycler with high multiplexing real-time PCR capabilities enables proprietary, new Liquid Array™ assay format for affordable syndromic panels – Expanded FluoroType™ MTBDR 2.0 Liquid Array assay provides highly differentiated tuberculosis (TB) detection and... Read more

October 16, 2018 Clinical Research/Diagn. Liq. Handling & Robotics M&A, Partnerships

Bruker Completes Acquisition of Majority Interest in Infectious Disease Molecular Diagnostics Company Hain Lifescience GmbH

BILLERICA, Mass., Oct. 16, 2018 /PRNewswire/ — Bruker Corporation (NASDAQ: BRKR) today announced that is has completed the acquisition of an 80% majority interest in Hain Lifescience GmbH, based in Nehren, Germany.  Hain is an infectious disease specialist with a broad range of molecular diagnostics (MDx) solutions for the detection of microbial and viral pathogens, as... Read more

October 15, 2018 Clinical Research/Diagn. M&A, Partnerships

Roche Diagnostics partners with DASA Group to create the world’s largest integrated core lab* today

Partnership that grows stronger While DASA has experienced unprecedented growth and success with their integrated lab, they don’t plan on slowing down. Alessandro Veiga states, “We haven’t stopped growing. DASA has an expectation to become a global leader in diagnostic medicine throughout the world.” DASA Group’s vision is to be the best company in the... Read more